Merck KGaA (OTCMKTS:MKGAF – Get Free Report) shares were up 5.2% during mid-day trading on Wednesday. The stock traded as high as $158.1360 and last traded at $157.7760. Approximately 93 shares traded hands during trading, a decline of 85% from the average session volume of 604 shares. The stock had previously closed at $149.9670.
Merck KGaA Stock Performance
The business has a fifty day moving average of $160.86 and a 200 day moving average of $150.08. The company has a market cap of $20.05 billion, a P/E ratio of 23.68 and a beta of 0.96. The company has a quick ratio of 0.84, a current ratio of 1.31 and a debt-to-equity ratio of 0.27.
Institutional Trading of Merck KGaA
Several large investors have recently bought and sold shares of the company. North Star Asset Management Inc. purchased a new position in shares of Merck KGaA during the 2nd quarter worth approximately $1,411,000. MASTERINVEST Kapitalanlage GmbH purchased a new position in shares of Merck KGaA in the 2nd quarter valued at approximately $4,896,000. Ames National Corp bought a new stake in shares of Merck KGaA during the second quarter valued at approximately $1,009,000. Elefante Mark B bought a new stake in shares of Merck KGaA during the second quarter valued at approximately $617,000. Finally, Pinnacle Holdings LLC purchased a new stake in Merck KGaA in the second quarter worth $1,487,000. 0.10% of the stock is owned by institutional investors.
Merck KGaA Company Profile
Merck KGaA is a Germany-based science and technology company headquartered in Darmstadt. Founded in 1668, it is one of the world’s oldest operating pharmaceutical and chemical companies. The business serves customers in more than 60 countries through three operating sectors: Healthcare, Life Science and Electronics.
The Healthcare sector develops and markets prescription medicines and specialty therapies, with activities focused on areas including oncology, neurology and immunology, fertility, and endocrinology.
Recommended Stories
- Five stocks we like better than Merck KGaA
- Dave’s Success Has Investors Split
- Hims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks
- Paychex Plunges, Providing the Entry Investors Have Been Waiting For
- The Case for Buying High-Yield General Mills Just Strengthened
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.
